Kerecis Omega3 Wound Plus SOC vs. SOC Alone in Treating Severe Diabetic Foot Ulcers and Forefoot Amputations (Odinn)
An Open Label, Randomized Controlled Study to Compare Healing of Severe Diabetic Foot Ulcers and Forefoot Amputations in Diabetics With and Without Moderate Peripheral Arterial Disease Treated With Kerecis Omega3 Wound and SOC vs. SOC Alone
Sponsor: Allderma Pharmaceuticals
A NA clinical study on Amputation and Dehiscence of Amputation Stump, this trial is completed. The trial is conducted by Allderma Pharmaceuticals and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2023 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
Sep 2022 — Mar 2023 [monthly]
Recruiting NA
-
Jan 2021 — Sep 2022 [monthly]
Recruiting NA
▶ Show 3 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting NA
-
Mar 2020 — Sep 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allderma Pharmaceuticals
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Endospin
- Kerecis Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .